Street. LEOUIS, Sept. 29, 2022 (GLOBE NEWSWIRE) — Stereotactic (NYSE: STXS), the pioneer and world leader in minimally invasive endovascular surgical robotics, today announced its attendance at the 6th Annual International Meeting of the Heart Robot Society. Navigation (SCRN) in Budapest from 29-30 September.
SCRN is an independent, physician-led, non-profit organization with global membership and local chapters in North America, Europe and Asia. SCRN was formed with a mission to advance clinical awareness, scientific research, and technological innovation of robotic techniques in cardiology. The SCRN meeting hosts cardiologists, colleagues, innovators, industry leaders and scientists to discuss, debate, challenge, share, educate and learn with peers. This year’s conference will feature more than 30 faculty members and more than 100 registered participants from more than 20 countries.
The in-person and virtual hybrid event includes multiple presentations on stereotaxic technology, clinical value and innovations. The full agenda is available on the SCRN website. Some noteworthy presentations include initial clinical experience with the Genesis RMN system in multiple hospitals, use of robotics in complex atrial and ventricular arrhythmias, use of pulse field ablation with robotics, remote and collaboration robotics, alternative access through the arm, and robotics Associated with various mapping techniques and synergistic imaging.
“We are excited to support SCRN and see its growth in a strong and dynamic physician community,” said David Fischel, Stereotaxis Chairman and CEO. “We look forward to connecting with attendees at SCRN who share our passion for advancing electrophysiology, challenging the limits of technology, and improving patient care with robotics.”
Stereotactic is the world leader in innovative robotic technologies designed to enhance the treatment of arrhythmias and to perform endovascular procedures. Its mission is to discover, develop and deliver automated systems, tools and information solutions to the interventional laboratory. These innovations help clinicians deliver unprecedented patient care with robotic accuracy and safety, expand access to minimally invasive treatment, and enhance productivity, connectivity, and intelligence in the operating room. Stereotactic technology has been used to treat more than 100,000 patients across the United States, Europe, Asia and elsewhere. For more information, please visit www.stereotaxis.com.
This press release includes statements that may constitute “forward-looking” statements, and usually contain the words “believes,” “estimates,” “projects,” “expects,” or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially. Factors that would cause or contribute to such differences include, but are not limited to, the Company’s ability to manage expenses at sustainable levels, market acceptance of the Company’s products, the impact of global economic conditions on customers’ ability and willingness to purchase technology, competitive factors and changes resulting from policy Health care, dependence on outside vendors, timing of regulatory approvals, the impact of pandemics or other disasters, and other risks discussed in the Company’s periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no guarantee that the Company will recognize revenue related to purchase orders and other commitments because some of these purchase orders and other commitments are subject to possibilities beyond the Company’s control and may be revised, modified, delayed or canceled.
|Investor contacts:||Media contact:|
|David L Fishel||Bethany Schlutter|
|Chairman and CEO||Marketing and Communications Manager|
|Chief Financial Officer|
#International #Meeting #Society #Cardiac #Robotics